Achieve Life Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Tables)

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2018

Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis

The following table presents information about our assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value (in thousands):

March 31, 2018	Level 1		Level 2		Level 3		Total
Assets
Cash	$	1,133	$	—	$	—	$	1,133
Money market securities (cash equivalents)		3,032		—		—		3,032
Restricted cash (Note 7)		272		—		—		272
Total assets	$	4,437	$	—	$	—	$	4,437
Liabilities
Warrants	$	—	$	—	$	—	$	—

Summary of Cash, Cash Equivalents and Short-Term Investments

Cash, cash equivalents and short-term investments consist of the following (in thousands):

			Gross		Gross
	Amortized		Unrealized		Unrealized		Estimated
March 31, 2018	Cost		Gains		Losses		Fair Value
Cash	$	1,133	$	—	$	—	$	1,133
Money market securities		3,032		—		—		3,032
Total cash and cash equivalents	$	4,165	$	—	$	—	$	4,165
Money market securities (restricted cash)		272		—		—		272
Total restricted cash	$	272	$	—	$	—	$	272